[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess [18F] -fluciclatide as a biomarker of response to
pazopanib and to evaluate the efficacy and safety of the combination of pazopanib and
paclitaxel in platinum-resistant ovarian cancer patients.